Hillstream BioPharma Signs an Exclusive Option Agreement to Advance Next-Generation Anti-MUC1-C Agents for Drug Resistant Cancers

January 31, 2023

https://www.globenewswire.com/news-release/2023/01/31/2598280/0/en/Hillstream-BioPharma-Signs-an-Exclusive-Option-Agreement-to-Advance-Next-Generation-Anti-MUC1-C-Agents-for-Drug-Resistant-Cancers.html

Development expected to capitalize upon tumor targeting Quatramers™

MUC1-C could be effective against a number of drug resistant cancers such as metastatic triple negative breast cancer (TNBC), small cell lung cancer (SCLC), merkel cell carcinoma (MCC) and neuroendocrine prostate cancer (NEPC)

Read more at globenewswire.com

Related news for (HILS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.